Biosimilars/Biobetters Pipeline Directory        
The most comprehensive and cost-effective follow-on biopharmaceuticals (biosimilars, biobetters and biogenerics) pipeline resource 

  • Find competing products and companies; product/API licensing sources; collaborators and partners; customers for your products, technologies and services
  • Over 1,500 product records:  840 biosimilars, 515 biobetters, 146 reference products; plus 682 involved company records [4/24/2017]
  • Available in multiple formats:
    • Directory/book/PDF format - PDF file ready for use or printing; 1-time delivery of current data
    • Web database (Products and Companies) subscription - for those needing online access and updates; plans for individuals and company-wide access
  • Developed by the author of BIOPHARMA:  Biopharmaceuticals in the U.S. and European Markets, still the only information resource/reference specializing in biopharmaceuticals, but no longer being updated, wit it now the "The Reference Products' Reference." 
  • Sales/fulfillment handled by BioPlan Associates, Inc.
  • Satisfaction guaranteed!  Full refund within 1 month, e.g., if you do not learn information that critically affects your company.

Description/Flyer:  Further information
Users Guide
Contact/Order/Inquiry form
Enter password for database access: followed by CR/enter

Biosimilars/Biobetters Pipeline Database - Top Level Data (as of 1/18/2017)

o

  • product entries = 1454
  • pipeline products (biosimilars + biobetters) = 1306
  • biosimilars = 797
  • biobetters = 507
  • ref. products = 146
  • companies = 669
The Biosimilars/Biobetters Pipeline Directory only covers recombinant proteins (great majority) and other cell culture/fermentation-manufactured protein products. 
[Note, biosimilar and biobetter U.S. and EU launchable dates (patent, data and market exclusivity expirations) are reported for the >145 reference products in BIOPHARMA, "The Reference Products Reference]." 
Follow-on products containing rather (bio)similar active agents are classed as either:
  • Biosimilar - products that are much the same, including products on-track for approval or approved by formal biosimilar mechanisms (in highly-regulated countries/major markets), generally with GMP manufacture and rigorous biosimilarity analyatical and clinical testing. 
  • Biobetter - products that are too different compared to other approved products to be approved as biosimilars; generally includes something innnovative or different vs. its reference and other similar producs; generally with GMP manufacture and rigorous biosimilarity analyatical and clinical testing 
  • Biogenerics - subset of biosimilars primarily marketed in lesser- and non-regulated developing country markets; generally not on-track for approval or approved by formal biosimilar mechanisms; generally not with GMP manufacture and rigorous biosimilarity testing and trials). 

Near-term economic impact includes biosimilars sooner or later for the ~45, nearly all recombinant, mostly monoclonal antibody, products with over $1 billion/year sales, and 20+ others with sales over $500 million/year. 

The table above shows country or regions and their numbers of associated biosimilars and biobetters.


Note, multiple companies can be involved with each product.

Some Popular Targeted Reference Products
[No. of biosimilars by reference product]
Epoetin alfa 81
Neupogen 58
Rituxan 54
Herceptin 46
Humira 35
Avastin 33
Enbrel 33
Neulasta 28
Remicade 17
Lantus 13
Insulin and analogs 61
Interferons (alfa) 63
Somatropins 35
Interferons (beta) 29
Cancer indications 455
mAbs, mAb fragments      291

Companies With the Largest Biosimilars Pipelines (10 or more)

Harvest Moon Pharmaceuticals USA, Inc. 28
Bioviz Technologies Pvt. Ltd. 25
Pfizer. 21
BioXpress Therapeutics S.A. 20
Reliance Life Sciences Pvt. Ltd. 18
Creative Biomart Inc. 15
Dong-A Pharmaceutical. 15
Inbiopro Solutions Pvt Ltd. 14
LG Life Sciences Ltd. 14
Mylan Labs. 14
Bio Sidus S.A. 12
Biocon Ltd. 13
Chemo Group (Grupo Insud ) 13
Dr. Reddy's Labs. 13
AXXO GmbH 12
Amega Biotech 11
BioGenomics Ltd. 11
Green Cross Corp. 11
Sandoz AG/Novartis AG 11
SciGen Ltd. (Bioton) 11
Viropro Inc. 11
BioPartners GmbH (Bioton) 11
Cassara Biotech 10
Intas Biopharmaceuticals Ltd. 10
Zydus Cadilla Healthcare Ltd. 10

Biosimilarspipeline.com Information Resources A variety of unique follow-on biopharmaceutical-related information resources are available or planned:

Some related articles by the database author:

Need a Consultant With Biosimilars Expertise? - Contact Biotechnology Information Institute for world-class expertise concerning biopharmaceutical information, products, technologies, and related market, technology and policy assessments.  

    Contact information:

    Sales handled by

      BioPlan Associates, Inc.
      2275 Research Blvd., Suite 500
      Rockville, MD 20850
      Tel:  301-921-5979
      Fax:  301-926-2455
      Email:  biosimilars@bioplanassociates.com